Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) exert pleiotropic effects on endocrine pancreas and nervous system. Expression of GIP and GIP receptor (GIPR) in neurons, their roles in neurogenesis, synaptic plasticity, neurotransmission, and neuromodulation uniquely position GIPR for therapeutic applications in neurodegenerative disorders. GIP analogs acting as GIPR agonists attenuate neurobehavioral and neuropathological sequelae of neurodegenerative disorders in preclinical models, e.g. Alzheimer's disease (AD), Parkinson's disease (PD), and cerebrovascular disorders. Modulation of GIPR signaling offers an unprecedented approach for disease modification by arresting neuronal viability decline, enabling neuronal regeneration, and reducing neuroinflammation. Growth-promoting effects of GIP signaling and broad-based neuroprotection highlight the therapeutic potential of GIPR agonists. Areas covered: This review focuses on the role of GIPR-mediated signaling in the central nervous system in neurophysiological and neuropathological conditions. In context of neurodegeneration, the article summarizes potential of targeting GIPR signaling for neurodegenerative conditions such as AD, PD, traumatic brain injury, and cerebrovascular disorders. Expert opinion: GIPR represents a validated therapeutic target for neurodegenerative disorders. GIPR agonists impart symptomatic improvements, slowed neurodegeneration, and enhanced neuronal regenerative capacity in preclinical models. Modulation of GIPR signaling is potentially a viable therapeutic approach for disease modification in neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 2×
“For AD, investigational disease-modifying therapies comprise of approximately 70% of total clinical trial underway at various phases underscoring the need for developing novel interventions [7].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Protein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675 · cited 1×
“Current investigational approaches for disease modification are based on the ‘proteinopathy’ hypothesis of reducing or clearing the plaque burden of abnormally folded proteins in most neurodegenerative disorders [8].”
BackgroundGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · cited 1×
“aggregation inhibitors, tyrosine kinase inhibitors, sigma-2 receptor modulator, RAGE antagonists) are being investigated in the various phases of clinical trials, however with limited success so far, highlighting the urgent need to develop novel interventions for AD [84].”
BackgroundSynaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Nyberg, J., Anderson, M. F., Meister, B., Alborn, A.-M., Ström, A.-K., Brederlau, A., Illerskog, A.-C., Nilsson, O., Kieffer, T. J., Hietala, M. A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4920-04.2005 · Cited by 191
Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration
Spielman, L. J., Little, J. P., & Klegeris, A. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.004 · Cited by 182 · cited 1×
“Nonneuronal glial cells, the microglia, astrocytes, and oligodendrocytes, in response to injury or infection, get activated and release inflammatory mediators like TNF-α, IL-1β, IL-6, and NFκB, leading to neuroinflammation [44].”
BackgroundLu, M., Wheeler, M. B., Leng, X. H., & Boyd, A. E. (1993) · Endocrinology · doi:10.1210/endo.132.1.8380389 · Cited by 151 · cited 1×
“GIPR is positively coupled to adenylyl cyclase and increases intracellular cAMP, leading to Ca influx and activation of protein kinase A-cAMP response element binding protein (PKA-CREB)-dependent signal transduction in β-pancreatic cells [23].”
Background
Cited by
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“In addition, the activation of GLP-1R was shown to promote synaptic plasticity and axonal growth (30), and stimulate adult neurogenesis (90).”
BackgroundKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings
Regazzo, D., Bertazza, L., Galletta, E., Barollo, S., Mondin, A., Zovato, S., Iacobone, M., Zilio, E., Scaroni, C., Radu, C. M., et al. (2022) · Endocrine-Related Cancer · doi:10.1530/erc-21-0258 · Cited by 17
Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection
Caruso, I., Cignarelli, A., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154272 · Cited by 11
Metadata
- Authors
- Verma, M. K., Goel, R., Krishnadas, N., & Nemmani, K. V. S.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-06-22
- Volume
- 22
- Issue
- 7
- Pages
- 615-628
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2807782219
- Cited by
- 21
- References
- 14
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. https://app.cochat.ai/papers/10.1080/14728222.2018.1487952
- The paper
- Verma, M. K., Goel, R., Krishnadas, N., & Nemmani, K. V. S. (2018). Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1487952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.